Literature DB >> 28983061

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.

Konstantin Byrgazov1, Chantal Blanche Lucini1, Peter Valent2, Oliver Hantschel3, Thomas Lion4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28983061      PMCID： PMC5777206          DOI： 10.3324/haematol.2017.176347

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

2.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Authors:  Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A Repasky; Jeffrey Chen; Peter Wells; Ciarán N Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W Murray; Krister Wennerberg
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962

3.  Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

Authors:  Tianjun Zhou; Lois Commodore; Wei-Sheng Huang; Yihan Wang; Mathew Thomas; Jeff Keats; Qihong Xu; Victor M Rivera; William C Shakespeare; Tim Clackson; David C Dalgarno; Xiaotian Zhu
Journal:  Chem Biol Drug Des       Date:  2010-11-30       Impact factor: 2.817

4.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Authors:  Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

5.  BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Authors:  Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

6.  Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Authors:  Michael W Deininger; J Graeme Hodgson; Neil P Shah; Jorge E Cortes; Dong-Wook Kim; Franck E Nicolini; Moshe Talpaz; Michele Baccarani; Martin C Müller; Jin Li; Wendy T Parker; Stephanie Lustgarten; Tim Clackson; Frank G Haluska; Francois Guilhot; Hagop M Kantarjian; Simona Soverini; Andreas Hochhaus; Timothy P Hughes; Victor M Rivera; Susan Branford
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

7.  Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Authors:  M S Zabriskie; C A Eide; D Yan; N A Vellore; A D Pomicter; S L Savage; B J Druker; M W Deininger; T O'Hare
Journal:  Leukemia       Date:  2015-11-19       Impact factor: 11.528

8.  Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.

Authors:  Konstantin Byrgazov; Chantal Blanche Lucini; Bettina Berkowitsch; Margit Koenig; Oskar A Haas; Gregor Hoermann; Peter Valent; Thomas Lion
Journal:  Oncotarget       Date:  2016-11-22

9.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

Authors:  R Kastner; A Zopf; S Preuner; J Pröll; N Niklas; P Foskett; P Valent; T Lion; C Gabriel
Journal:  Eur J Cancer       Date:  2013-12-20       Impact factor: 9.162
View more
  8 in total

1.  Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Authors:  Sara De Santis; Margherita Martelli; Cecilia Monaldi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Manuela Mancini; Samantha Bruno; Claudia Venturi; Katerina Machova Polakova; Thomas Ernst; Dianna Maar; Adam Corner; Michele Cavo
Journal:  Leukemia       Date:  2022-07-30       Impact factor: 12.883

Review 2.  Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges.

Authors:  Simona Soverini; Renato Bassan; Thomas Lion
Journal:  J Hematol Oncol       Date:  2019-04-23       Impact factor: 17.388

3.  The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.

Authors:  H Jonathan G Lindström; Ran Friedman
Journal:  BMC Cancer       Date:  2020-05-07       Impact factor: 4.430

4.  CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.

Authors:  Mathias Schneeweiss-Gleixner; Konstantin Byrgazov; Gabriele Stefanzl; Daniela Berger; Gregor Eisenwort; Chantal Blanche Lucini; Susanne Herndlhofer; Sandra Preuner; Klara Obrova; Petra Pusic; Nadine Witzeneder; Georg Greiner; Gregor Hoermann; Wolfgang R Sperr; Thomas Lion; Michael Deininger; Peter Valent; Karoline V Gleixner
Journal:  EBioMedicine       Date:  2019-11-21       Impact factor: 8.143

5.  BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia.

Authors:  Barbara Peter; Gregor Eisenwort; Irina Sadovnik; Karin Bauer; Michael Willmann; Thomas Rülicke; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Gregor Hoermann; Alexandra Keller; Dominik Wolf; Martin Čulen; Georg E Winter; Thomas Hoffmann; Ana-Iris Schiefer; Wolfgang R Sperr; Johannes Zuber; Jiří Mayer; Peter Valent
Journal:  Am J Hematol       Date:  2022-07-18       Impact factor: 13.265

Review 6.  BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.

Authors:  Gustavo P Amarante-Mendes; Aamir Rana; Tarcila Santos Datoguia; Nelson Hamerschlak; Gabriela Brumatti
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

Review 7.  Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.

Authors:  Tariq I Mughal; Naveen Pemmaraju; Bethan Psaila; Jerald Radich; Prithviraj Bose; Thomas Lion; Jean-Jacques Kiladjian; Raajit Rampal; Tania Jain; Srdnan Verstovsek; Abdulraheem Yacoub; Jorge E Cortes; Ruben Mesa; Giuseppe Saglio; Richard A van Etten
Journal:  Hematol Oncol       Date:  2020-09-04       Impact factor: 5.271

Review 8.  Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Authors:  Sara De Santis; Cecilia Monaldi; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Onco Targets Ther       Date:  2022-01-25       Impact factor: 4.147
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.